Pharmaceutical Aneurysm Stabilisation Trial

Recruiting

• Conditions: Abdominal aortic aneurysm - Inflammation - Cardiovascular diseases - Metalloproteinases - Doxycycline - Pharmaceutical Treatment

• Registration Number: NL-OMON23083
• Lead Sponsor: uts Ohra

Brief Summary

/A

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 28 February 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 300

Inclusion Criteria

Patients under surveillance with small aneurysms (i.e. 3.5-5.0 cm), and in larger
AAA in patients who are unfit for or refuse open operation or endovascular intervention of their larger AAA (i.e. exceeding 5.0 cm).

Exclusion Criteria

1. Unable to comply with follow up.

2. Contra-indications for doxycycline:

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
* Aneurysm growth at t=18 months as determined by ultrasound

Secondary Outcome Measures

Name	Time	Method
* Secondary outcome measures are: <br /> <br>- growth at 6 and 12 months<br /><br>- need for elective aneurysm repair<br /><br>- rupture<br /> <br>- death<br /><br>- an inventory of possible side effects (questionnaire). <br /><br><br /><br>Moreover, posible effect on atherosclerosis will be evaluated by:<br /><br>- assesment of intima media thickness (carotid artery)<br /><br>- plasma inflmmatory markers<br /><br>- endothelial cell markers<br /><br>- spirometric testing.